ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 169

Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?

Jasvinder A. Singh1, Rekha Ramachandaran2, Jie Zhang3, Fenglong Xie4, Shuo Yang5, Huifeng Yun6 and Jeffrey R. Curtis2, 1Department of Medicine, University of Alabama, Tuscaloosa, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, 4Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 5Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: coronary artery disease, Diabetes, gout, heart disease and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid guidelines have a different pathway for diabetes patients. Gout has been shown to be a risk factor for myocardial infarction and stroke in some cohort studies.  It is not known whether gout is as strong a risk factor for acute myocardial infarction as diabetes, a question we attempted to answer with the current study. We compared the incidence of hospitalized acute myocardial infarction (MI) between patients with DM and or RA.

Methods: We used claims data from 2006 to 2010 that included a mix of private and public health plans with medical and pharmacy coverage.  Four mutually exclusive cohorts were identified: 1) Gout and DM; 2) Gout only; 3) DM only; and 4) neither gout nor diabetes.  Patients with prior CHD during a baseline period of ³ 1 year were excluded using relevant diagnosis codes. Outcomes were defined as at least one overnight stay, unless the patient died, plus the presence of ³ 1 inpatient hospital claim with a discharge ICD-9 code 410.x1 in any position for Acute MI or presence of ICD-9 code for stroke (430.XX, 431.xx, 433.x1(433.01, 433.11, 433.21, 433.31, 433.81, 433.91), 434 (434.01, 434.11, 434.91 ,excluding 434.x0), 436.XX) in any position. We compared the age- and gender-specific incidence of acute MI and stroke rates across the four cohorts.  We assessed univariate and multivariable-adjusted hazard rates of acute MI and stroke.

Results:   A total of 298,929 patients had diabetes, 91999 had gout, 37573 had both and 1,099,373 had neither. Compared to patients with neither, those with gout or DM or both were older.  Incidence of acute MI was lowest in patients with neither, followed by patients with gout, diabetes and both –e.g. in men, respective rates/1000 person-years were 0.0138, 0.0271, 0.0291 and 0.0475. Similar trend were noted for stroke. In unadjusted analyses, both gout and DM increased the risk of acute MI and stroke by a similar magnitude (Table 1). In multivariable-adjusted analyses, gout was associated with significantly lower risk of acute MI than diabetes, but no significant differences were noted between gout and DM for the risk of stroke (Table 1).  Patients with both gout and DM had 1.26 and 1.29-times higher hazard of acute MI and stroke, compared to patients with diabetes only (Table 1).  

Conclusion: Gout increases the risk of incident MI significantly but does not appear to be a CHD risk equivalent comparable to DM for incident MI. Gout is a CHD risk equivalent comparable to DM for stroke. Having both gout and DM confers incremental risk compared to DM alone for both MI and stroke.

Table 1. Unadjusted and multivariable-adjusted hazards of MI and stroke with gout and diabetes

Unadjusted, MI

Multivariable-adjusted, MI

Unadjusted, Stroke

Multivariable-adjusted, Stroke

Hazard ratio (95% CI); p-value

Hazard ratio (95% CI); p-value

Hazard ratio (95% CI); p-value

Hazard ratio (95% CI); p-value

Gout and diabetes

1.92 (1.82, 2.04)

p<0.0001

1.26 (1.19, 1.34)

p<0.0001

1.88 (1.74, 2.02)

p<0.0001

1.29 (1.20, 1.40)

p<0.0001

Gout, no diabetes

1.02 (0.96, 1.07)

p=0.57

0.82 (0.77, 0.86)

p<0.0001

1.28 (1.21, 1.36)

p<0.0001

1.00 (0.94, 1.06)

p=0.96

No diabetes, no gout

0.37 (0.36, 0.38)

p<0.0001

0.55 (0.53, 0.57)

p<0.0001

0.42 (0.41, 0.44)

p<0.0001

0.58 (0.56, 0.60)

p<0.0001

Diabetes, no gout

ref

ref

ref

ref


Disclosure:

J. A. Singh,

Takeda, Savient,

2,

consultant fees from Savient, Takeda, Regeneron and Allergan,

5;

R. Ramachandaran,
None;

J. Zhang,
None;

F. Xie,
None;

S. Yang,
None;

H. Yun,

Amgen,

2;

J. R. Curtis,

Roche, Genentech, UCB Pharma, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie,

2,

Roche, Genentech, UCB Pharma, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, AbbVie,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-gout-a-coronary-heart-disease-risk-equivalent-similar-to-diabetes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology